SEER

Galorath Selects Walt & Company as Public Relations Agency of Record

Retrieved on: 
Wednesday, November 29, 2023
Workforce, SEER, PR, Policy, Engineering, Organization, Forecasting, Dan Galorath

CAMPBELL, Calif., Nov. 29, 2023 /PRNewswire/ -- Walt & Company, an award-winning Silicon Valley tech public relations and social media agency, today announced it has been named PR agency of record by Galorath, the premier provider of cost, scheduling, and should-cost estimation solutions and consulting services. Leveraging four decades of experience and success, Galorath empowers organizations with the tools and talent needed to optimize project results and drive cost-effectiveness.

Key Points: 
  • CAMPBELL, Calif., Nov. 29, 2023 /PRNewswire/ -- Walt & Company, an award-winning Silicon Valley tech public relations and social media agency, today announced it has been named PR agency of record by Galorath , the premier provider of cost, scheduling, and should-cost estimation solutions and consulting services.
  • Leveraging four decades of experience and success, Galorath empowers organizations with the tools and talent needed to optimize project results and drive cost-effectiveness.
  • Galorath has allowed thousands of projects around the world to be successfully delivered as planned," said Charles Orlando, chief marketing officer, Galorath.
  • We added Walt & Company to the Galorath team based on its strategic, creative and technical public relations capabilities and experience."

Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500

Retrieved on: 
Wednesday, November 8, 2023
Fintech, Health, Therapy, Deloitte Technology Fast 500, Genomics, SEER, Telecommunications, Seer, Proteome, Proteomics, Biotechnology, Pharmaceutical industry

(NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company was selected as “Proteomics Solution of the Year” in the 2023 BioTech Breakthrough Awards program as well as being named to the 2023 Deloitte Technology Fast 500 .

Key Points: 
  • (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company was selected as “Proteomics Solution of the Year” in the 2023 BioTech Breakthrough Awards program as well as being named to the 2023 Deloitte Technology Fast 500 .
  • “We're thrilled to receive accolades from both BioTech Breakthrough and Deloitte, as these awards underscore our unwavering dedication to innovation, collaboration, and our mission to advance our understanding of human health.
  • Seer also announced today that it ranked 5 on the Deloitte Technology Fast 500, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.
  • Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2019 to 2022.

SEER’S MV TECHNOLOGIES RECEIVES NEW CONTRACTS FOR $1.5MM AND INCREASES ANNUAL MEDIA SUPPLY CONTRACTS

Retrieved on: 
Thursday, November 2, 2023
Paragon, ET, Food, MV, Parsons Corporation, Tree, SEER, Marketing, Combs, World energy supply and consumption, CO, Ontario Basic Income Pilot Project, Kingdom, Natural gas, Heating, ventilation, and air conditioning, Renewable energy, H2S

It is estimated the new systems will collectively use approximately $500,000 of MV’s Axtrap™ media on an annual basis.

Key Points: 
  • It is estimated the new systems will collectively use approximately $500,000 of MV’s Axtrap™ media on an annual basis.
  • This will add significantly to the existing baseline of over $1MM in media sales.
  • MV also recently received a purchase order for an H2SPlus™ for a large Canadian-based food processor.
  • Each project becomes a valuable addition to the more than 140 existing projects already in MV Technologies ’ portfolio throughout North America,” said Tom Jones, President of MV.

Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program

Retrieved on: 
Wednesday, November 1, 2023
Data analysis, Plasma, Biomarker, Phenotype, Research, Nanoparticle, Protein, Disease, SEER, Ecosystem, Biology, COE, Workflow, Metabolomics, Proteome, Proteomics, Fine chemical

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that Panome Bio has joined its COE Program.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that Panome Bio has joined its COE Program.
  • Panome Bio is a metabolomics and proteomics services company that provides biopharma innovators unparalleled access to the biomolecules closest to phenotype using its proprietary Next Generation Metabolomics™ technology.
  • Panome Bio joins Seer’s global COE network of leading service providers, who are all committed to accelerating the adoption of unbiased, deep proteomics at scale.
  • Seer COEs have been selected for their demonstrated expertise in proteomics, their ability to deliver the highest quality service, and their commitment to partnering to expand the ecosystem around deep, unbiased proteomics using Seer’s technology.

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Retrieved on: 
Tuesday, October 31, 2023
American Cancer Society, RT, Patent, Biomarker, Management of prostate cancer, Shuttle, Georgetown University, SBIR, Intellectual property, Prostate cancer, Surveillance, Aggression, Database, Risk, SEER, National Cancer Institute, Bangladesh Technical Education Board, NIH, Cancer, IP, Patient, Failure, Pharmaceutical industry, Medical imaging, Epidemiology

ROCKVILLE, Md., Oct. 31, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered into an exclusive agreement to license certain intellectual property (IP) from Georgetown University to advance Shuttle Pharma's predictive biomarker program for prostate cancer.

Key Points: 
  • ROCKVILLE, Md., Oct. 31, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered into an exclusive agreement to license certain intellectual property (IP) from Georgetown University to advance Shuttle Pharma's predictive biomarker program for prostate cancer.
  • Anatoly Dritschilo, M.D., CEO of Shuttle Pharma, commented, "Prostate cancers vary in their aggressiveness and in their responses to treatment.
  • The American Cancer Society estimates that 1 in 8 men will be diagnosed with prostate cancer during his lifetime.
  • Dr. Dritschilo expanded, "Our mission is to accelerate investigation of the prostate cancer metabolite-based predictive assay to improve outcomes of radiation therapy.

Azra AI SmartPath™: Empowering Hospitals with a Proven AI-Driven Tumor Registry Management Solution

Retrieved on: 
Thursday, October 19, 2023
Technology, Hospitals, Health Technology, Software, Health, General Health, Data Management, Artificial Intelligence, Oncology, Computer security, Health information management, NCI, HIM, Electronic health record, Pathology, Conference, National Cancer Institute (Egypt), Multimedia, Surveillance, Artificial intelligence, Empathy, Seamless, Registry, Risk, SEER, Hospital, Abstract, National Cancer Institute, EHR, Cancer, Medical device, Medical imaging, Epidemiology

SmartPath is an innovative AI-powered solution that offers essential support to tumor registry teams within hospitals and healthcare facilities nationwide.

Key Points: 
  • SmartPath is an innovative AI-powered solution that offers essential support to tumor registry teams within hospitals and healthcare facilities nationwide.
  • Many hospitals have been negatively affected, and we stand ready to collaborate with them and any hospital looking to enhance their tumor registry workflows.
  • Efficiency and Speed: With SmartPath, hospitals can expect a remarkable increase in efficiency and speed in tumor registry operations.
  • Your Tumor Registry teams can quickly adapt to this state-of-the-art solution without the need for extensive IT support.

AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360

Retrieved on: 
Tuesday, October 3, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Janssen Pharmaceuticals, Disease, Journal of Oncology Pharmacy Practice, PharMerica, HRR, ADP, Abiraterone acetate, CI, National Cancer Institute, Janssen, ADT, Toxicity, Pharmacy, Prednisone, Death, BRCA2, Hospital, Specialty pharmacy, HIV disease progression rates, Patient, Risk, Testosterone, SEER, Johnson & Johnson, Gonadotropin-releasing hormone, BRCA, FDA, PARP, Orchiectomy, Phase, CYP17, Prostate cancer, Pharmaceutical industry, Epidemiology

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson for AKEEGA™ (niraparib and abiraterone acetate).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson for AKEEGA™ (niraparib and abiraterone acetate).
  • Patients should be selected for therapy based on an FDA-approved test for AKEEGA.
  • Patients taking AKEEGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
  • “Onco360 is thankful for the opportunity to partner with the team at Janssen and become a specialty pharmacy provider for AKEEGA,” said Benito Fernandez, Chief Commercial Officer.

SEER’S JOINT VENTURE PARTNER IN THE KINGDOM OF SAUDI ARABIA HAS BEEN AWARDED LARGE PILOT PROJECT INVOLVING SEVERAL OF THE LARGEST PUBLIC PARKS IN THE KINGDOM AS PART OF THE “GREEN RIYADH” PROJECT

Retrieved on: 
Tuesday, September 12, 2023
Private sector, Partnership, World energy supply and consumption, Vision 2030, The Green Initiative, Climate, Health, Enterprise, Parsons Corporation, RCRC, Tree, Quality of life, Green Initiative, KSA, Carbon, CO, ET, Royal commission, Soil, Sustainable Development Goals, Water, SEER, Ecosystem, PH, Environment, CO2, Royal Commission for Riyadh City, Fine chemical, Renewable energy, Agriculture, Kingdom

The project will entail applying SEER’s proprietary Pellechar™ and a specially-engineered biochar provided by Biochar Now (“BCN”), one of SEER’s strategic domestic partners.

Key Points: 
  • The project will entail applying SEER’s proprietary Pellechar™ and a specially-engineered biochar provided by Biochar Now (“BCN”), one of SEER’s strategic domestic partners.
  • BCN’s patented production process as enabled it to create a custom, adjusted-pH biochar specifically tailored for the Saudi environment.
  • During this pilot project, both SEER and ET will be coordinating and working closely with Parsons Corporation ( https://www.parsons.com/ ) (“Parsons”).
  • We are also discussing the prospect of working with our joint venture partner to manufacture our Pellechar and biochar in the Kingdom.

ELREXFIO™ (elranatamab-bcmm), Now Available from Onco360

Retrieved on: 
Wednesday, September 13, 2023
FDA, Health, Pharmaceutical, Clinical Trials, Oncology, REMS, Cytokine release syndrome, Malignancy, US FDA, Mitigation, CD3, CRS, Multiple myeloma, Immunomodulatory imide drug, Cancer, Bone marrow, National Cancer Institute, Cohort study, Pharmacy, CAR, US, Specialty pharmacy, Patient, B cell, SEER, ADC, Diagnosis, RRMM, Caregiver, Phase, ORR, BCMA, Pfizer, Disease, Vaccine, Pharmaceutical industry, Epidemiology

Onco360®, the nation’s leading independent Specialty Pharmacy will be a pharmacy provider for Elrexfio™ (elranatamab-bcmm).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy will be a pharmacy provider for Elrexfio™ (elranatamab-bcmm).
  • This indication is approved under accelerated approval based on response rate and durability of response.
  • Multiple myeloma, a rare malignancy, accounts for 1.8% of all new cancer cases in the United States.
  • The five-year overall survival (OS) for patients with multiple myeloma is 59.8%.3
    ELREXFIO is commercialized by Pfizer.

Midea Presents Green Vision Blue Future at IFA 2023: Unveiling Revolutionary Smart Home Solution

Retrieved on: 
Thursday, September 7, 2023
United States–Africa Leaders Summit 2022, SCOP, Exhibition, Blue Angel, Overalls, R290, Miele, GWP, Collection, Extreme, SEER, Heat, System, Legislation, Heating, ventilation, and air conditioning, Lumber, Midea

Under the theme of "Green Vision Blue Future," Midea showcases its unwavering commitment to sustainability and innovation by presenting an impressive range of products that prioritize environmental protection and energy-saving capabilities, catering to the diverse needs of different scenarios and users.

Key Points: 
  • Under the theme of "Green Vision Blue Future," Midea showcases its unwavering commitment to sustainability and innovation by presenting an impressive range of products that prioritize environmental protection and energy-saving capabilities, catering to the diverse needs of different scenarios and users.
  • Midea's green products lineup is designed to embrace eco-friendly solutions that make a positive impact on our planet without compromising on performance.
  • Furthermore, in response to the European energy crisis and the evolving needs of users, Midea introduced its latest one-stop green smart home solution.
  • With an unwavering commitment to highlighting the importance of establishing a green and efficient global supply chain, Midea has taken strides to make changes.